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measured at 7-14 days after AMI positively correlated with clinical markers of disease severity such as peak creatine kinase (CK), 8, 12 or C-reactive protein, 7 and others reported the association between elevated VEGF levels on admission and high Killip classification 15 or the severity of coronary artery disease. 15 Moreover, in another study high VEGF levels measured just after the onset of acute coronary syndrome (ACS) were associated with a poor outcome. 16 The findings from those reports are inconsistent with the cardioprotective effects of VEGF reported by in vivo and in vitro studies. These discrepancies may be ascribed to the fact that the VEGF levels were measured just after the onset when unstable hemodynamics might affect systemic VEGF production, or that the infarct-related arteries were not necessary reperfused in those studies.
The association between peak VEGF levels and clinical outcome in AMI patients who underwent primary PCI successfully within 24 h of onset has not been evaluated. We herein investigated the relationship between the VEGF levels at 7 days after the onset of AMI after successful revascularization by PCI, and the incidence of major adverse cardiovascular and cerebrovascular events (MACCE) during a 6-month follow-up.
Methods

Study Design and Study Population
We conducted a prospective, multicenter observational study of AMI, named the Nagoya Acute Myocardial Infarction Study (NAMIS), in which 18 collaborating hospitals in central Japan participated. The NAMIS was designed to assess the clinical variables, therapeutic procedures and subsequent clinical events in AMI patients. The eligibility criteria were that patients had been admitted to a participating hospital for AMI, and underwent successful recanalization within 24 h of symptom onset. Patients with AMI because of coronary spasm and/or procedural causes were excluded from the study. Information was obtained from hospital medical records, by questionnaire surveys carried out every 6 months and by direct interviews with patients, their family members, or physicians in charge. Written informed consent was obtained from all of the patients. The study protocol was approved by each hospital's ethics committee. Among the 917 patients enrolled in the NAMIS from December 2003 to November 2010, 879 patients had blood sample data available, including plasma VEGF levels at 7 days after the onset of AMI.
Clinical Definitions and Endpoints
The diagnosis of AMI required the presence of an increase in the serum CK concentration to more than twice the upper limit of normal (or >400 IU/L), and one of the following 2 criteria: (1) typical chest pain or chest discomfort lasting longer than 30 min, and (2) typical ischemic electrocardiographic changes. The primary endpoint was MACCE during the 6-month period after AMI, defined as cardiac death, recurrent ACS, unplanned hospital readmission for heart failure, and stroke. Cardiac death was defined as death from cardiovascular cause or unexpected death within 24 h of symptom onset. Recurrent ACS, which was the composite of ST elevation myocardial infarction (MI), non-ST elevation MI, and unstable angina, was diagnosed when patients had clinical symptoms such as chest pain, shortness of breath, and syncope, accompanied by evidence of a culprit lesion on coronary angiogram. Heart failure was diagnosed when patients with clinical symptoms including dyspnea, shortness of breath, and peripheral edema together with evidence of heart failure by chest roentgenogram or ultrasound examination. Stroke was defined when patients had a newly developed neurological deficit and relevant findings on computed tomography or magnetic resonance imaging. All events were strictly evaluated by the independent Endpoint Evaluation Committee in a manner blinded to all of the patients' clinical information. Hypertension was defined as having a baseline blood pressure ≥140/90 mmHg or taking antihypertensive agents. Patients receiving medications for diabetes mellitus or with baseline hemoglobin A1c ≥6.9% were considered to have diabetes mellitus. Dyslipidemia was diagnosed when patients after overnight fasting had low-density lipoprotein cholesterol ≥140 mg/dl, triglycerides ≥150 mg/dl or high-density lipoprotein cholesterol <40 mg/dl, or were being treated with lipidlowering agents. Preinfarction angina was defined as the presence of chest pain or discomfort before the onset of AMI. The left ventricular ejection fraction was calculated by echocardiography using the Teichholz formula at discharge. We obtained CK levels on admission and every 6 h until 24 h after PCI. The estimated glomerular filtration rate based on serum creatinine was calculated using the 3-variable equation, proposed by the Japanese Society of Nephrology (estimated glomerular filtration rate [ml · min - 17 and chronic kidney disease was defined as an estimated glomerular filtration rate <60 ml · min -1 · 1.73 m −2 .
Laboratory Examinations
The plasma VEGF levels, as well as other parameters including complete blood cell counts, liver function test results, renal function test results, lipid profiles, and brain natriuretic peptide (BNP) levels were measured 7 days after the onset of AMI. Samples were obtained after a 6-h fast because the biochemical factors, including the lipid profile and blood glucose level, were examined using the same samples. All components of the blood examinations were measured at Mitsubishi Chemical Medience Co Ltd, Tokyo, Japan. Plasma VEGF was measured by an enzyme-linked immunosorbent assay (Quantikine TM , R&D Systems, USA). The detection limit for plasma VEGF was 15.6 pg/ml. The intra-assay coefficient of variation was 3.39-6.00% for plasma VEGF.
Statistical Analysis
The patients were categorized into 3 groups according to the tertiles of plasma VEGF levels (low, middle, high). The relationship between the 3 groups and MACCE within 6 months was analyzed. For each subject, the follow-up time was calculated from the date of AMI onset to the date of MACCE or the time when the last outcome information was available, whichever occurred first. All results for continuous variables are expressed as the means ± standard deviations or medians (quartiles). Differences among the 3 groups were assessed using a 1 way ANOVA followed by Scheffé's tests or a Kruskal-Wallis analysis. The categorical variables are shown as the numbers of patients (percentages). The differences in prevalence were assessed using chi-square or Fisher exact tests. The correlation between the VEGF levels at 7 days after onset and max CK levels was demonstrated by using the scatter diagram method after logarithmic transformation with Pearson's correlation coefficient. The survival curves were calculated by the Kaplan-Meier method and analyzed by the log-rank test. Unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the primary endpoint were calculated using the Cox proportional hazard models. Covariates assessed in the Cox univariate analyses were the VEGF tertile, patient Clinical Implications of VEGF After AMI age, sex, history of diabetes mellitus, history of dyslipidemia, history of hypertension, smoking status, higher Killip class at admission, the presence of chronic kidney disease, presence of multivessel disease, BNP (after logarithmic transformation), and the use of statin therapy before the onset of AMI. Any covariates that were significant in the univariate analyses (P<0.10) were incorporated into a multivariate analysis. Because there were strong positive associations between a higher Killip class and the BNP level, we excluded the higher Killip class from the Cox multivariate analysis. Next, the chisquare tests or Fisher exact tests, and the age-adjusted logistic regression analyses were conducted to examine the relationships between the 3 groups and the probability of the main components of MACCE. In addition, subgroup analyses of the association of the VEGF groups and MACCE rate divided according to Killip class, max CK levels (divided by the median level of 2,423 IU/L), BNP levels (divided by BNP=200 pg/ml) and statin therapy before onset of AMI were conducted because VEGF is reported to be susceptible to the influence of ischemia or unstable hemodynamics. We performed further analyses to identify the factors that account for the group with the worst outcome, including the variables with a P-value <0.05 in the univariate analyses. Differences were considered to be statistically significant at P<0.05. The analyses were performed using the SPSS software program version 19.0 for Windows (SPSS Japan, Inc, Tokyo, Japan).
Results
Patients' Characteristics
The present study included 708 males (80.5%) and 171 females (19.5%), with a median age of 64 years. Their plasma VEGF levels were found to be widely distributed (111.0 [42. .0] pg/ml). There were 84 (9.6%) patients with plasma VEGF lower than the lower detection limit of 15.6 pg/ml. Patients were stratified into 3 groups according to the tertiles of plasma VEGF levels: low (<61.0 pg/ml [n=293]), middle (61.0-176.0 pg/ml [n=294]), and high (≥176.1 pg/ml [n=292]). Values are mean ± SD, medians (quartiles), or numbers (%). ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; AMI, acute myocardial infarction; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; BG, blood glucose; BNP, brain natriuretic peptide; CK, creatine kinase; LVEF, left ventricular ejection fraction; SD, standard deviation; CKD, chronic kidney disease. *CKD was defined as an estimated glomerular filtration rate <60 ml · min -1 · 1.73 m -2 . † Analyzed after logarithmic transformation. MATSUDAIRA K et al.
The clinical characteristics and laboratory data of the patients in the 3 groups are summarized in Table 1 . Patients in the low group were significantly younger, and had significantly higher levels of high-density lipoprotein cholesterol than the other groups. The prevalence of hypertension and diabetes mellitus tended to be lower among the patients in the low group. There was a significant positive correlation between VEGF group and Killip class on admission. Although some previous reports indicated that the VEGF levels after AMI correlate with the max CK levels, no such relationship was observed after logarithmic transformation in the present study ( Figure S1) . The patients in all the 3 groups had received similar oral medications before the onset of AMI, except for 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins). The prevalence of statin therapy before the onset of AMI was the least frequent (P=0.042) in the low group (7.5%) compared with those in the middle (13.9%) and high groups (11.6%). There were no significant differences in the use of β-blockers, renin-angiotensin system inhibitors, or statins at discharge (data not shown).
Relationship Between Plasma VEGF Level and MACCE During a 6-Month Follow-up
Of all the patients, 870 (99.0%) were followed for 6 months. The other 9 patients (1.0%) were lost to follow-up because of job-related moves (n=3) or withdrawal of consent (n=6). All patients, including these 9 patients, were included in the analyses until the last visit or the date when they withdrew their consent. During 6-month follow-up period, 41 MACCE occurred: 5 cardiac deaths, 20 unplanned hospital readmissions for heart failure, 14 cases of recurrent ACS, and 2 strokes. The estimated survival curves for MACCE among the 3 groups showed that the risk of MACCE was the highest in patients in the low VEGF group and that the patients in the middle VEGF group showed the best outcome. Differences between the low group and the other groups were apparent from approximately 60 days after the onset of AMI (Figure) .
The unadjusted Cox regression analyses revealed that in the low group, when the middle group was used as the reference, an older age, history of diabetes mellitus, higher Killip class on admission, chronic kidney disease, multivessel disease, and higher BNP levels at 7 days after admission were significantly associated with a higher incidence of MACCE ( Table 2 ). The significance of low VEGF level for predicting MACCE was consistent even after adjusting for all these covariates (HR 2.67, 95%CI 1.18-6.06, P=0.019). In contrast, patients in the high group experienced more MACCE than the middle group, but there was no statistically significant difference.
Plasma VEGF Levels and Components of MACCE
Among the components of MACCE, patients in the low group experienced a significantly higher incidence of recurrent ACS events than those in the other groups (3.4% vs. 0.7% and 0.7%; P=0.010) ( Table 3) , as was indicated in the age-adjusted logistic regression analysis when the middle group was used as the reference (HR 5.33, 95%CI 1.15-24.65, P=0.032). There were linear-by-linear associations between the VEGF groups and MACCE rate among patients with Killip=1 or BNP <200 pg/ml, but not among patients with Killip ≥2 or BNP ≥200 pg/ml. Abbreviations see in Tables 1,2 . MATSUDAIRA K et al.
Incidence of MACCE Stratified by Killip Class, BNP Level and Statin Treatment Before Onset
The high VEGF group did not show the best outcome. We hypothesized that VEGF augmentation caused by heart failure might be involved in the increased MACCE in the high VEGF group. Therefore, we performed the stratified analyses shown in Table 4 . There was a negative linear-by-linear association between the VEGF groups and MACCE rate among patients with Killip=1 or BNP <200 pg/ml (P for trend=0.007 in patients with Killip=1, and 0.048 in patients with BNP <200 pg/ml), but there was no association in patients with Killip ≥2 or BNP ≥200 pg/ml (P for trend=0.951 in patients with Killip ≥2, and 0.440 in patients with BNP ≥200 pg/ml; Table 4 ).
Factors Related to Low VEGF on Day 7 After AMI
The logistic regression analyses revealed that being in the low VEGF group was significantly related to younger age (age Table 5 ).
Discussion
The major finding of the present study is that a low plasma VEGF level 7 days after the onset of AMI was associated with a significantly higher incidence of MACCE during the following 6 months. Of the components of MACCE, patients with a low plasma VEGF level experienced a significantly higher incidence of recurrent ACS than the other groups. With regard to the determinant of a low VEGF level at 7 days, younger age and the absence of statin therapy before the onset of AMI were the significant factors. To the best of our knowledge, this is the first report to demonstrate that patients with low plasma VEGF levels after AMI are at an increased risk for MACCE during the following 6 months. VEGF has favorable effects on both vascular endothelial survival and endothelial healing in patients with AMI. The possible explanations for the associations between the low VEGF levels and high incidence of MACCE, especially ACS, include the following. First, it is possible that the endothelium in the low VEGF group may be more severely damaged than that in the higher groups, because VEGF increases the tolerance of the endothelium to ischemia 4 and activates pro-survival processes. 18 Another possible mechanism is that the healing process of the endothelium at the plaques and damaged myocardium may be insufficient in patients in the low group. Increased VEGF derived from the infarcted and periinfarcted areas is thought to induce vasodilatation through an increase in nitric oxide production, 19 to promote endothelial regeneration at the ruptured or eroded plaques, and to induce angiogenesis, 1,2 all of which result in an increase in the blood supply. 5, 6 Such effects can ameliorate residual ischemia, and prevent additional myocardial necrosis. Because VEGF is the key molecule responsible for the angiogenic response in ischemic tissues, 1,2 the plasma VEGF levels may reflect the potential power to heal the infarcted area. Both the finding that the estimated survival curves appeared to diverge from approximately 60 days after onset of AMI, and that patients in the low group experienced more ACS events, support this notion. Because successful revascularization of the infarct-related arteries with PCI immediately after the onset of AMI makes it possible to supply a certain amount of reparative blood flow to the infarcted myocardium, the functional recovery of the endothelium has greater implications among such patients with AMI.
The findings of the present study are in sharp contrast to the previous report by Heeschen et al, 16 which showed that the elevation of the serum VEGF level was associated with a higher incidence of death or non-fatal MI in patients with ACS. The differences in the studies may be associated with the fact that we obtained the blood samples 7 days after the onset of AMI symptoms, whereas Heeschen et al measured the serum VEGF level just after the onset of ACS. Therefore, the hemodynamic abnormalities and inflammation resulting as a consequence of myocardial damage at the time of measurement of VEGF would be more resolved in our study than in the previous study. Moreover, the VEGF levels in the previous study were modulated by the ischemia from jeopardized myocardium, because the VEGF levels were measured before reperfusion of the infarct-related arteries. The extent of ischemia, 20 concomitant hypoxia, 21 and worsening of systemic hemodynamics 15 all increase the plasma VEGF level. Therefore, the high VEGF levels reported in the prior study may Table 1 . Clinical Implications of VEGF After AMI reflect a larger 'area at risk' of MI, the patient's condition complicated by heart failure, or patients with severe systemic atherosclerosis. Similarly, we could not show a graded decrease in the MACCE rate with the progression of VEGF group. In the stratified analysis we showed that low VEGF was predictive for the incidence of MACCE in patients without heart failure, whereas the predictive significance of VEGF for MACCE would be complicated in AMI patients with heart failure. The augmentation of VEGF by unstable hemodynamics or concomitant heart failure may contribute to the result. The VEGF levels positively correlated with Killip class on admission (Table 1) , which was associated with the increased risk for MACCE. VEGF levels did not correlate with the max CK levels in our study, although prior studies 8, 12 showed a correlation between max CK and peak VEGF levels. The difference between the present study and the prior studies is that all of our patients underwent successful primary PCI early after the onset of AMI, whereas some patients in the prior studies did not undergo primary PCI. The successful myocardial salvage from early recanalization by PCI might be the cause of this result. This is supported by the report from Soeki et al, 7 all of whose patients also underwent successful primary PCI. Therefore, we should differentiate AMI patients in a stable condition after successful primary PCI from those with heart failure or without primary PCI when we assess the relationship between VEGF levels and the risk for MACCE.
We assessed the plasma VEGF levels at 7 days after onset, which we previously reported to be the peak after the onset of AMI. 14 The serial course of VEGF levels could differ in patients with primary PCI in comparison to those without, because early treatment of stenosis by primary PCI results in more stable reperfusion which might influence VEGF production derived from the infarcted area. In addition, primary PCI might affect the VEGF-producing cells, leading to altered VEGF production. This hypothesis is supported by previous reports 11- 13 showing that the VEGF levels reach a peak at days 10-14 in a study population that included some AMI patients without primary PCI. In contrast, VEGF levels in the culture medium of peripheral blood mononuclear cells (PBMNCs) after incubation for 24 h were maximally elevated 7 days after the onset of AMI. PBMNCs play critical roles in vascular repair process and angiogenesis, 22,23 so the VEGF levels at 7 days after AMI would be augmented by such cellular contexts to facilitate repair of the injured endothelium. Collectively, we speculate that VEGF levels obtained 7 days after the onset of AMI adequately reflect the physiological function of VEGF among patients who undergo successful primary PCI.
In our subanalysis, we evaluated the possible independent factors predicting low VEGF levels at 7 days after the onset of AMI. It was surprising that younger age was significantly associated with the low VEGF group, because previous studies have suggested a reduction in VEGF levels according to age. 24 Advanced age was a major risk factor not only for coronary but peripheral artery disease in the Framingham study. 25 Therefore, although speculative, it is likely that the elderly patients had more severe systemic atherosclerosis that induced more VEGF release. Actually, our patients tended to have more atherosclerotic risk factors, such as hypertension and diabetes mellitus, as their age advanced (odds ratio by increasing 10 years increase of age: 1.327, P<0.001 for hypertension; 1.107, P=0.151 for diabetes mellitus). Prior statin treatment was another determinant for VEGF levels 7 days after AMI. Statins increase VEGF in various cell types through the activation of hypoxiainducible factor (HIF-1), 26-28 the principal transcription factor involved in the response to hypoxia. 21 Statin therapy before the onset of AMI also might influence the VEGF levels after AMI. The effectiveness of statin therapy for patients at high risk of an AMI has been established. 29, 30 For example, chronic administration of statins before onset has been reported to reduce myocardial necrosis 31 and improve the event free survival during 6-month follow-up 32 in patients with AMI. More studies are necessary, but our results suggest that statins may influence the vascular repair process after AMI, partially though the regulation of VEGF.
Study Limitations
First, the rate of MACCE during the 6-month follow-up period in our study was relatively low. Second, we have no data on the history of generalized atherosclerotic disease in our patients, including cerebral vessel disease and peripheral arterial disease, before the onset of AMI. However, because the patients in the low group less frequently had atherosclerotic risk factors, the highest risk for MACCE in the low group was not likely to be attributed to such systemic diseases. Third, we measured the plasma VEGF levels at only 1 time point at 7 days after the onset of AMI, which is reported as its peak. Further studies are therefore needed to determine the suitable time point for VEGF measurement to predict the prognosis. Fourth, we have no data on the other biomarkers involved in angiogenesis and tissue repair processes. The exploration of other biomarkers in conjunction with VEGF in patients with AMI also has enormous significance and is a subject of future investigation.
Conclusions
Low plasma VEGF levels at 7 days after the onset of AMI were associated with a significantly increased risk for MACCE, especially for ACS, during 6-month follow-up. The absence of statin therapy before AMI was 1 determinant of a lower plasma VEGF level.
